BC Innovations | Jan 17, 2019
Emerging Company Profile

Zelluna’s solid TCR plans

Zelluna Immunotherapy A/S is using a portfolio of HLA class II-restrictive TCRs to develop autologous cell therapies that could unleash a broader immune attack on solid tumors than other TCR-based cell therapies in development. CEO...
BioCentury | Nov 12, 2012
Emerging Company Profile

Targovax: Ras to the rescue

Targovax A/S 's peptide-based vaccine improved survival in an investigator-led Phase I/II trial in resected pancreatic cancer, and the company is planning its own Phase I/II trial this year. The vaccine works by going after...
BioCentury | Apr 23, 2012
Emerging Company Profile

APIM: Besting the stress defense

Chemotherapies and other cancer drugs induce apoptosis by causing genotoxic and other cellular stresses, but the ability of cancer cells to overcome such stress can limit efficacy. By targeting a master regulator of cellular responses...
BC Extra | Feb 2, 2012
Financial News

Targovax raises $2.2M in series A

Targovax A/S (Lysaker, Norway) raised NOK13 million ($2.2 million) in a series A round led by existing investor Radium Hospital Research Foundation. New investors Birk Venture and RO Invest participated, along with existing owners. Targovax's...
Items per page:
1 - 4 of 4
BC Innovations | Jan 17, 2019
Emerging Company Profile

Zelluna’s solid TCR plans

Zelluna Immunotherapy A/S is using a portfolio of HLA class II-restrictive TCRs to develop autologous cell therapies that could unleash a broader immune attack on solid tumors than other TCR-based cell therapies in development. CEO...
BioCentury | Nov 12, 2012
Emerging Company Profile

Targovax: Ras to the rescue

Targovax A/S 's peptide-based vaccine improved survival in an investigator-led Phase I/II trial in resected pancreatic cancer, and the company is planning its own Phase I/II trial this year. The vaccine works by going after...
BioCentury | Apr 23, 2012
Emerging Company Profile

APIM: Besting the stress defense

Chemotherapies and other cancer drugs induce apoptosis by causing genotoxic and other cellular stresses, but the ability of cancer cells to overcome such stress can limit efficacy. By targeting a master regulator of cellular responses...
BC Extra | Feb 2, 2012
Financial News

Targovax raises $2.2M in series A

Targovax A/S (Lysaker, Norway) raised NOK13 million ($2.2 million) in a series A round led by existing investor Radium Hospital Research Foundation. New investors Birk Venture and RO Invest participated, along with existing owners. Targovax's...
Items per page:
1 - 4 of 4